4//SEC Filing
Rodman David Malcom 4
Accession 0001672659-26-000004
CIK 0001933414other
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 8:43 PM ET
Size
13.7 KB
Accession
0001672659-26-000004
Insider Transaction Report
Form 4
Rodman David Malcom
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-01-09$16.00/sh+2,170$34,720→ 63,974 total - Sale
Common Stock
[F1]2026-01-09$33.27/sh−2,170$72,196→ 61,804 total - Exercise/Conversion
Common Stock
[F1]2026-01-12$1.08/sh+6,348$6,856→ 68,152 total - Sale
Common Stock
[F1][F2]2026-01-12$32.32/sh−6,348$205,143→ 61,804 total - Exercise/Conversion
Stock Option
[F1][F3]2026-01-09−2,170→ 28,218 totalExercise: $16.00Exp: 2033-02-09→ Common Stock (2,170 underlying) - Exercise/Conversion
Stock Option
[F1][F3]2026-01-12−6,348→ 38,092 totalExercise: $1.08Exp: 2032-07-11→ Common Stock (6,348 underlying)
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.01 to $32.93. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
Signature
/s/ Adam Levy, Attorney-in-fact|2026-01-13
Documents
Issuer
Mineralys Therapeutics, Inc.
CIK 0001933414
Entity typeother
Related Parties
1- filerCIK 0001672659
Filing Metadata
- Form type
- 4
- Filed
- Jan 12, 7:00 PM ET
- Accepted
- Jan 13, 8:43 PM ET
- Size
- 13.7 KB